Mizuho analyst Anthony Petrone lowered the firm’s price target on ResMed (RMD) to $265 from $280 and keeps an Outperform rating on the shares ...

Wall Street analysts forecast that ResMed (RMD) will report quarterly earnings of $2.36 per share in its upcoming release, pointing to a year-over-year increase of 10.8%. It is anticipated that ...

Shares of ResMed Inc. RMD shed 1.16% to $211.49 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to 5,275.70 and Dow ...

Wall Street expects a year-over-year increase in earnings on higher revenues when ResMed (RMD) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important ...

Morgan Stanley analyst David Bailey maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD – ...

ResMed Inc. closed 18.65% short of its 52-week high of $263.05, which the company reached on January 30th.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. Resmed, Inc. holds a major position as designer, manufacturer, as well as a distributor in the worldwide market ...

Home CPAP device maker Resmed is launching a small, disposable wearable to help diagnose cases of obstructive sleep apnea.  | ...

ResMed shares have been caught up in the recent market volatility. Has this created a buying window for ResMed shares?

SAN DIEGO – Resmed has announced that its home sleep apnea test, NightOwl, is now available across the U.S.

Morgan Stanley analyst David Bailey initiated coverage of ResMed (RMD) with an Overweight rating and $280 price target The company has a market-leading position in the obstructive sleep apnea ...